Der­ma­vant says Vta­ma top­i­cal cream works in PhI­II eczema tri­al

Der­ma­vant Sci­ences said its plaque pso­ri­a­sis-ap­proved cream Vta­ma al­so worked in pa­tients with atopic der­mati­tis, as the Roivant sub­sidiary push­es to­ward a la­bel ex­pan­sion of the top­i­cal.

In a 406-pa­tient ran­dom­ized tri­al, Der­ma­vant said Vta­ma met the main goal, lead­ing to a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in an in­ves­ti­ga­tor as­sess­ment of le­sions.

“These are the fun ones, and we’re re­al­ly pleased with the up­date we have to share to­day,” Roivant CEO Matt Gline said to kick off a Wednes­day morn­ing call. He called it the “ninth con­sec­u­tive pos­i­tive Phase III study com­ing out of the Roivant fam­i­ly” and said a sup­ple­men­tal NDA will be shipped to FDA in the first quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER